Table 3.
Medications, Management and Healthcare Utilization of COPD During the COVID-19 Epidemic
| Variables | N (%) |
|---|---|
| Times of visiting to any hospital | |
| 0 | 85 (55.6) |
| 1 | 51 (33.3) |
| ≥2 | 17 (11.1) |
| Causes of visiting Respiratory Clinic in any hospital a | |
| Getting medicine for COPD | 60 (88.2) |
| Review and assessment of COPD | 4 (5.9) |
| Aggravation of respiratory symptoms | 4 (5.9) |
| Pharmacological treatment | |
| Inhaled SABA | 4 (2.6) |
| Inhaled SAMA | 2 (1.3) |
| ICS/LABA | 82 (53.6) |
| LAMA | 87 (56.9) |
| Oral theophylline | 9 (5.9) |
| The doses of medicine prescribed in one outpatient visit b | |
| 2 weeks | 3 (2.6) |
| 1 month | 43 (37.1) |
| 2 months | 39 (33.6) |
| 3 months | 31 (26.7) |
Notes: Data are presented as n (%); aThis was calculated in patients who ever visited Respiratory Clinic in any hospital (n = 68); bThis was calculated in patients having long-term pharmacological treatment (n = 116).
Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LAMA, long–acting muscarinic antagonist.